

CIN No:- L24230PB2006PLC030341  
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/21-22/BSE-37

Date...14-Feb-2022.....

To

Department of Corporate Affairs  
BSE Limited  
P.J. Towers, Dalal Street  
Mumbai -400001

Ref: Script code – 540694

Sub: Outcome of Board Meeting pursuant to Reg. 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Monday, 14<sup>th</sup> February, 2022 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2021 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company.

The Board meeting was commenced at 04:30 P.M. and concluded at 08:15 P.M.

This is for your information. Kindly take the same on your record.

Thanking you

Yours faithfully

For ANG Lifesciences India Limited



Rajesh Gupta  
(Managing Director)



# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.

E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. ....

Independent Auditor's Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of  
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of ANG Lifesciences India Limited ("Holding Company") and its Subsidiary (the Holding and its subsidiaries together referred to as "the Group") for the quarter ended 31<sup>st</sup> December, 2021 ("the statement") attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations")
2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.
5. The Statement includes the result of the following entities:-  
Mansa Print & Publishers Limited





# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.  
E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. ....

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Amritsar  
Date: 14.02.2022

For Raman Wadhwa & Co.  
Chartered Accountants  
(Ishant Sharma)  
Partner  
Reg. no. 012037N  
M. No. 527055  
UDIN: 22527055ACEUWQ4371





# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.

E-mail: ishantsharma2187@yahoo.com

Ref. No. .... Independent Auditor's Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Dated. ....

To

The Board of Directors of  
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended 31<sup>st</sup> December, 2021 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations")
2. This statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Amritsar  
Date: 14.02.2022

For Raman Wadhwa & Co.  
Chartered Accountants

(Ishant Sharma)  
Partner

Reg. no. 012037N

M. No. 527055

UDIN: 22527055ACEUWQ4371

ANG Life Sciences India Limited

Reg: SCO-113 Darbara Complex Ranjit Avenue B Block Amritsar -143001

Unaudited Financial Results (Consolidated) for the period ended 31 December 2021

		(₹ in lakh)					
Particulars	For the quarter ended 31 December 2021 (unaudited)	For the quarter ended 30 September 2021 (unaudited)	For the quarter ended 31 December 2020 (unaudited)	For the period ended 31 December 2021 (unaudited)	For the period ended 31 December 2020 (unaudited)	For the year ended 31 March 2021 (audited)	
<b>Income</b>							
I Revenue from operations	4,961.02	8,946.40	3,221.40	25,892.40	11,834.16	15,437.90	
II Other income	15.58	9.95	4.17	33.19	16.84	55.59	
III <b>Total income (I+II)</b>	<b>4,976.60</b>	<b>8,956.35</b>	<b>3,225.57</b>	<b>25,925.59</b>	<b>11,850.99</b>	<b>15,493.48</b>	
<b>IV Expenses</b>							
Cost of materials consumed	4,366.00	5,259.01	2,316.33	16,663.64	8,287.67	10,825.93	
Changes in inventories of finished goods, work-in-progress and stock in trade	(1,124.24)	191.37	(341.16)	(580.88)	(204.50)	(429.88)	
Employee benefits expense	557.90	537.55	440.95	1,553.03	1,067.52	1,434.60	
Finance costs	200.24	164.08	92.92	498.75	252.05	351.95	
Depreciation and amortisation expenses	153.41	119.87	34.55	326.91	91.78	133.43	
Other expenses	629.12	973.77	635.71	2,792.14	1,580.99	2,181.54	
<b>Total expenses</b>	<b>4,782.43</b>	<b>7,245.66</b>	<b>3,179.30</b>	<b>21,253.59</b>	<b>11,075.50</b>	<b>14,497.57</b>	
V <b>Profit before exceptional items and tax (III-IV)</b>	<b>194.17</b>	<b>1,710.69</b>	<b>46.27</b>	<b>4,671.99</b>	<b>775.49</b>	<b>995.91</b>	
VI Exceptional items	-	-	-	-	-	-	
VII <b>Profit before tax (V-VI)</b>	<b>194.17</b>	<b>1,710.69</b>	<b>46.27</b>	<b>4,671.99</b>	<b>775.49</b>	<b>995.91</b>	
<b>VIII Tax expense</b>							
Current tax	65.00	360.00	34.90	1,125.00	220.00	318.00	
Deferred tax	1.84	67.14	(10.43)	40.49	(10.01)	(6.55)	
IX <b>Profit for the year (VII-VIII)</b>	<b>127.33</b>	<b>1,283.55</b>	<b>21.80</b>	<b>3,506.50</b>	<b>565.50</b>	<b>684.46</b>	
<b>X Other comprehensive income/(expense)</b>							
Items that will not be reclassified to profit or loss	8.57	4.18	(23.42)	13.75	(70.25)	(93.66)	
Income-tax relating to above items	(2.16)	(1.05)	5.89	(3.46)	17.68	23.57	
XI <b>Total comprehensive income for the year (IX+X)</b>	<b>133.74</b>	<b>1,286.68</b>	<b>4.28</b>	<b>3,516.79</b>	<b>512.93</b>	<b>614.37</b>	
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,036.66	1,036.66	518.33	1,036.66	518.33	518.33	
XIII Other equity	-	-	-	-	-	4,109.39	
XIV Earnings per equity share (of ₹ 10/- each) (not annualised except for year ended 31 March 2021)							
Basic and diluted earnings per share	1.29	12.41	0.08	33.92	9.90	11.85	

See accompanying notes to the financial results.

For ANG Lifesciences India Limited

  
**Rajesh Gupta**  
 Managing Director  
 DIN:01423407

## Unaudited Financial Results (Standalone) for the period ended 31 December 2021

(₹ in lakh)

	Particulars	For the quarter ended 31 December 2021 (unaudited)	For the quarter ended 30 September 2021 (unaudited)	For the quarter ended 31 December 2020 (unaudited)	For the period ended 31 December 2021 (unaudited)	For the period ended 31 December 2020 (unaudited)	For the year ended 31 March 2021 (audited)
	<b>Income</b>						
I	Revenue from operations	4,711.91	8,768.44	3,221.40	25,279.95	11,834.16	15,437.90
II	Other income	13.46	11.48	4.17	32.82	16.84	55.59
III	<b>Total income (I+II)</b>	<b>4,725.37</b>	<b>8,779.92</b>	<b>3,225.57</b>	<b>25,312.77</b>	<b>11,850.99</b>	<b>15,493.48</b>
	<b>IV Expenses</b>						
	Cost of materials consumed	4,305.66	5,231.08	2,316.33	16,491.89	8,287.67	10,825.93
	Changes in inventories of finished goods, work-in-progress and stock in trade	(1,095.90)	259.46	(341.16)	(438.42)	(204.50)	(429.88)
	Employee benefits expense	477.31	461.67	440.95	1,330.76	1,067.52	1,434.60
	Finance costs	168.59	134.31	92.92	434.36	252.05	351.95
	Depreciation and amortisation expenses	134.63	103.44	34.55	274.99	91.78	133.43
	Other expenses	554.37	903.21	635.71	2,599.37	1,580.99	2,181.54
	<b>Total expenses</b>	<b>4,544.66</b>	<b>7,093.17</b>	<b>3,179.30</b>	<b>20,692.95</b>	<b>11,075.50</b>	<b>14,497.57</b>
V	<b>Profit before exceptional items and tax (III-IV)</b>	<b>180.71</b>	<b>1,686.75</b>	<b>46.27</b>	<b>4,619.82</b>	<b>775.49</b>	<b>995.91</b>
VI	Exceptional items	-	-	-	-	-	-
VII	<b>Profit before tax (V-VI)</b>	<b>180.71</b>	<b>1,686.75</b>	<b>46.27</b>	<b>4,619.82</b>	<b>775.49</b>	<b>995.91</b>
VIII	<b>Tax expense</b>						
	Current tax	65.00	360.00	34.90	1,125.00	220.00	318.00
	Deferred tax	(6.17)	60.74	(10.43)	51.71	(10.01)	(6.55)
IX	<b>Profit for the year (VII-VIII)</b>	<b>121.88</b>	<b>1,266.01</b>	<b>21.80</b>	<b>3,443.10</b>	<b>565.50</b>	<b>684.46</b>
X	<b>Other comprehensive income/(expense)</b>						
	Items that will not be reclassified to profit or loss	8.57	4.18	(23.42)	13.75	(70.25)	(93.60)
	Income-tax relating to above items	(2.16)	(1.05)	5.89	(3.46)	17.68	23.57
XI	<b>Total comprehensive income for the year (IX+X)</b>	<b>128.29</b>	<b>1,269.14</b>	<b>4.28</b>	<b>3,453.39</b>	<b>512.93</b>	<b>614.37</b>
XII	Paid-up equity share capital (Face value ₹ 10/- per share)	1,036.66	1,036.66	518.33	1,036.66	518.33	518.33
XIII	Other equity						4,109.39
XIV	Earnings per equity share (of ₹ 10/- each) (not annualised except for year ended 31 March 2021)						
	Basic and diluted earnings per share	1.24	12.24	0.08	33.51	9.90	11.85

See accompanying notes to the financial results.

For ANG Lifesciences India Limited



Rajesh Gupta  
Managing Director  
DIN:01423407

**ANG Life Sciences India Limited**

**Reg: SCO-113 Darbara Complex Ranjit Avenue B Block Amritsar -143001**

**Notes to financial results**

1. ANG Lifesciences India Limited is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials.
2. The above results of ANG Life Sciences India Limited ('the Company' or 'the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") have been prepared in accordance with the Indian Accounting Standard (IND AS)- 34 "Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter. The unaudited standalone and consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14 February 2022. The statutory auditors of the Company have carried out the limited review of the standalone and consolidated financial results for the quarter and period ended 31 December 2021.
3. The Company's primary business segment is reflected based on principal business activities carried on by the Company. Managing Director has been identified as being the Chief Operating\*Decision Maker ('CODM') and evaluates the Company's performance and allocates resources based on analysis of the variance performance indicators of the Company as a single unit. Therefore, there are no separate reportable business segments as per IND AS 108, 'Operating Segment'.
4. The Board of Directors of the Company have approved the issue of 5,183,315 bonus equity shares on the record date i.e. 23 September 2021 in the proportion of 1 (One) equity share of Rs. 10/- each for every 1 (One) Equity Shares of Rs. 10/- each held by the shareholders of the Company as on the record date.
5. During the period ended 31 December 2021, the Company has acquired Mansa Prints and Publishers Limited as per order of NCLT dated 18 March 2020 under Insolvency and Bankruptcy Code 2016 ,the proceedings of which was started on 28 February 2019 .The order of Hon'ble National Company Law Tribunal was pronounced on 18 March 2020 wherein the Resolution Plan of ANG Life Sciences India Limited was approved. The payment of Rs. 1350 lakhs was made by the Company against the allotment of 3,499,400 equity shares (99.98% holding) on 01 April 2021.
6. The Company has considered the impact of COVID-19, as incurred so far, in the standalone and consolidated financial results. The Company will continue to monitor any material changes to future economic conditions that may impact the carrying value assets of the Company.
7. The Company has migrated from BSE SME platform to main board of BSE w.e.f. 08 November 2021.
8. These financial results are available on the website of the Company at [www.anglifesciences.com](http://www.anglifesciences.com) and are also available on the website of Bombay Stock Exchange at [www.bseindia.com](http://www.bseindia.com).
9. Previous period figures have been re-grouped / reclassified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III of the Companies Act, 2013 effective from 01 April 2021.



For and on behalf of the Board of Directors of  
ANG Lifesciences India Limited

Rajesh Gupta  
(Managing Director)  
DIN:01423407

Place: Amritsar  
Date: 14 February 2022